Oncternal Therapeutics Future Growth
Future criteria checks 0/6
Oncternal Therapeutics's earnings are forecast to decline at 13.8% per annum while its annual revenue is expected to grow at 2.6% per year. EPS is expected to grow by 1.5% per annum.
Key information
-13.8%
Earnings growth rate
1.5%
EPS growth rate
Biotechs earnings growth | 20.7% |
Revenue growth rate | 2.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 08 Mar 2024 |
Recent future growth updates
Recent updates
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Oncternal: Solid Data In Tough-To-Treat Cancer
Jan 31Oncternal Therapeutics: Recent Success Points To A Bright Future
Jan 29Oncternal inks manufacturing deal with Miltenyi Biotec subsidiary
Jan 14Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies
Jan 07Oncternal Therapeutics soars after presenting data at ASH
Dec 07Oncternal Therapeutics shares dip 20% after raising 'bought deal' offering to $22.5M
Nov 18New data on lead drug propels Oncternal Therapeutics, up 78%
Nov 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1 | -56 | N/A | -52 | 1 |
12/31/2025 | 1 | -48 | N/A | -44 | 2 |
12/31/2024 | 0 | -34 | N/A | -39 | 3 |
12/31/2023 | 1 | -39 | -32 | -32 | N/A |
9/30/2023 | 1 | -42 | -35 | -35 | N/A |
6/30/2023 | 1 | -43 | -41 | -41 | N/A |
3/31/2023 | 1 | -46 | -39 | -39 | N/A |
12/31/2022 | 1 | -44 | -37 | -37 | N/A |
9/30/2022 | 2 | -41 | -34 | -34 | N/A |
6/30/2022 | 4 | -39 | -29 | -29 | N/A |
3/31/2022 | 4 | -35 | -29 | -29 | N/A |
12/31/2021 | 4 | -31 | -27 | -27 | N/A |
9/30/2021 | 5 | -26 | -24 | -24 | N/A |
6/30/2021 | 4 | -21 | -23 | -23 | N/A |
3/31/2021 | 4 | -18 | -19 | -19 | N/A |
12/31/2020 | 3 | -17 | -17 | -17 | N/A |
9/30/2020 | 3 | -19 | -17 | -17 | N/A |
6/30/2020 | 2 | -19 | -15 | -15 | N/A |
3/31/2020 | 3 | -37 | -17 | -17 | N/A |
12/31/2019 | 2 | -34 | -17 | -17 | N/A |
9/30/2019 | 2 | -31 | -16 | -16 | N/A |
6/30/2019 | 2 | -28 | -12 | -12 | N/A |
3/31/2019 | 3 | -7 | -7 | -7 | N/A |
12/31/2018 | 3 | -7 | -7 | -7 | N/A |
12/31/2017 | 2 | -10 | -9 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ONCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ONCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ONCT's revenue (2.6% per year) is forecast to grow slower than the US market (8.2% per year).
High Growth Revenue: ONCT's revenue (2.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ONCT's Return on Equity is forecast to be high in 3 years time